Author

María José García

IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU
IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU

María José García  et al.

IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU
IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU

DURABILITY AND SAFETY OF UPADACITINIB IN CROHN’S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: PRELIMINARY RESULTS FROM A SPANISH NATIONWIDE STUDY
DURABILITY AND SAFETY OF UPADACITINIB IN CROHN’S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: PRELIMINARY RESULTS FROM A SPANISH NATIONWIDE STUDY

María José García  et al.

EFFECTIVENESS AND SAFETY OF A SECOND-LINE RESCUE THERAPY IN HOSPITALISED PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS STEROID-REFRACTORY AFTER FAILING INFLIXIMAB OR CICLOSPORIN (REASUC STUDY)
EFFECTIVENESS AND SAFETY OF A SECOND-LINE RESCUE THERAPY IN HOSPITALISED PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS STEROID-REFRACTORY AFTER FAILING INFLIXIMAB OR CICLOSPORIN (REASUC STUDY)

María José García  et al.

EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB THERAPY FOR COMPLEX PERIANAL FISTULA IN CROHN’S DISEASE: THE HEAL STUDY
EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB THERAPY FOR COMPLEX PERIANAL FISTULA IN CROHN’S DISEASE: THE HEAL STUDY

María José García  et al.

INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THERAPEUTIC REQUIREMENTS AFTER COLECTOMY IN PATIENTS WITH ULCERATIVE COLITIS. RESULTS FROM THE RESERVO STUDY OF GETECCU
INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THERAPEUTIC REQUIREMENTS AFTER COLECTOMY IN PATIENTS WITH ULCERATIVE COLITIS. RESULTS FROM THE RESERVO STUDY OF GETECCU

María José García  et al.

EFFICACY OF BIOLOGICAL THERAPY FOR POUCHITIS AND OTHER INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THE QUESTION OF A SECOND ANTI-TNF AFTER ANTI-TNF FAILURE? RESULTS FROM THE RESERVO STUDY OF GETECCU
EFFICACY OF BIOLOGICAL THERAPY FOR POUCHITIS AND OTHER INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THE QUESTION OF A SECOND ANTI-TNF AFTER ANTI-TNF FAILURE? RESULTS FROM THE RESERVO STUDY OF GETECCU

María José García  et al.

ACCELERATED OR ESCALATED INDUCTION REGIMENS OF INFLIXIMAB FOR STEROID-REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS IN CLINICAL PRACTICE: DATA FORM THE ENEIDA REGISTRY
ACCELERATED OR ESCALATED INDUCTION REGIMENS OF INFLIXIMAB FOR STEROID-REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS IN CLINICAL PRACTICE: DATA FORM THE ENEIDA REGISTRY

María José García  et al.

THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB
THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB

María José García  et al.

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY

María José García  et al.

REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES
REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES

María José García  et al.

USTEKINUMAB AND VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE IN CLINICAL PRACTICE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY
USTEKINUMAB AND VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE IN CLINICAL PRACTICE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY

María José García  et al.

IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)
IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)

María José García  et al.

Item 1 - 13 / 13
1